Country
United Kingdom
The gene therapy developer Freeline Therapeutics Ltd has closed a $120 million extended Series C financing round in order to bring its lead programme for haemophilia B into a pivotal trial.
Full text available to subscribers only. Click here for information on subscribing to MedNous.